Salubris SAL0137 drug clinical trial application accepted

According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0137 (project code: SAL0137) has been accepted. SAL0137 is an orally administered small molecule drug developed by the company with independent intellectual property rights. The application submitted by the company is for the clinical trial of SAL0137 for the treatment of elevated lipoprotein(a)